Elite in Optic Nerve Atrophy

Piero Barboni

Bologna, IT 
Elite in Optic Nerve Atrophy
Bologna, IT 
OverviewLocationsClinical Research

Overview

Piero Barboni practices in Bologna, Italy. Mr. Barboni is rated as an Elite expert by MediFind in the treatment of Optic Nerve Atrophy. His top areas of expertise are Optic Nerve Atrophy, Leber Hereditary Optic Neuropathy (LHON), Wolfram Syndrome, Diabetes Insipidus (DI), and Cataract Removal.

His clinical research consists of co-authoring 128 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 68 articles and participated in 2 clinical trials in the study of Optic Nerve Atrophy.

Gender
Male

Locations

Bologna, 40123, Italy
Other Locations
Milan, Italy
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Biological, Device
Study Phase: Phase 3
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene
Enrollment Status: Completed
Publish Date: January 23, 2020
Intervention Type: Biological, Device
Study Phase: Phase 3
View 1 Less Clinical Trial

128 Total Publications

Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.
Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.
Journal: Investigative ophthalmology & visual science
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Barboni's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile